8-K: Genprex's Acclaim-3 Trial Advances to Highest Dose Group After Positive Safety Review

Genprex's Acclaim-3 clinical trial for Reqorsa gene therapy in combination with Tecentriq has successfully completed the 0.09 mg/kg dose group and is approved to escalate to the highest dose group of 0.12 mg/kg.

Summary

• Genprex has completed the 0.09 mg/kg dose group in the Phase 1 dose escalation portion of the Acclaim-3 clinical trial.
• The trial is evaluating Reqorsa gene therapy in combination with Tecentriq for patients with extensive stage small cell lung cancer (ES-SCLC).
• The Safety Review Committee (SRC) has approved the escalation to the highest dose group of 0.12 mg/kg.
• No dose-limiting toxicities were observed in the 0.09 mg/kg dose group.
• The Phase 1 portion aims to determine the maximum tolerated dose or recommended Phase 2 dose.
• The Phase 2 expansion portion will enroll 50 patients at 10 to 15 U.S. sites.
• The primary endpoint of the Phase 2 portion is the 18-week progression-free survival rate.
• A Phase 2 futility analysis will be performed after the 25th patient reaches 18 weeks of follow-up.
• The company anticipates starting the Phase 2 expansion in the second half of 2024.
• The Acclaim-3 trial has received FDA Fast Track and Orphan Drug Designations.

Sentiment

Score: 7

Explanation: The document presents positive progress in the clinical trial with no safety concerns, but also includes standard risk disclosures, resulting in a moderately positive sentiment.

Positives

• The successful completion of the 0.09 mg/kg dose group with no dose-limiting toxicities is a positive sign for the safety profile of the treatment.
• The approval to escalate to the highest dose group indicates confidence in the treatment's potential.
• The trial's FDA Fast Track and Orphan Drug Designations could expedite the regulatory approval process.
• The planned Phase 2 expansion will provide more data on the treatment's efficacy.

Risks

• The trial's success is dependent on the number of patients needed to be enrolled in the 0.12 mg/kg dose group.
• The company's ability to advance the clinical development, manufacturing and commercialization of its product candidates is subject to risks and uncertainties.
• The timing and success of clinical trials and regulatory approvals are not guaranteed.
• The company's future growth and financial status are subject to risks, including the ability to maintain compliance with Nasdaq listing requirements and obtain capital.
• The company's commercial and strategic partnerships are subject to risks, including the ability of third-party vendors to perform and scale up manufacturing.

Future Outlook

The company anticipates completing enrollment in the Phase 1 dose escalation portion and starting the Phase 2 expansion portion in the second half of 2024, dependent on the number of patients needed to be enrolled in the 0.12 mg/kg dose group.

Industry Context

This announcement is relevant to the oncology and gene therapy sectors, where there is a high unmet need for effective treatments for aggressive cancers like small cell lung cancer. The combination therapy approach is also a growing trend in cancer treatment.

Comparison to Industry Standards

• The use of a combination therapy approach, combining a gene therapy (Reqorsa) with an immune checkpoint inhibitor (Tecentriq), is consistent with current trends in cancer treatment.
• The trial's design, including a dose escalation phase followed by an expansion phase, is a common approach in early-stage clinical trials.
• The primary endpoint of 18-week progression-free survival is a standard metric used in lung cancer trials.
• Companies like Roche (manufacturer of Tecentriq) and others developing gene therapies for cancer are direct comparables.

Stakeholder Impact

• Positive results from the trial could benefit patients with ES-SCLC by providing a new treatment option.
• Positive trial results could increase shareholder value.
• The company's employees are likely to be impacted by the progress of the trial.

Next Steps

• Enrollment in the 0.12 mg/kg dose group of the Phase 1 dose escalation portion of the trial.
• Completion of the Phase 1 dose escalation portion of the trial.
• Start of the Phase 2 expansion portion of the trial.
• Performance of a Phase 2 futility analysis after the 25th patient reaches 18 weeks of follow-up.

Key Dates

Keywords

Reqorsa, Gene Therapy, Small Cell Lung Cancer, Clinical Trial, Acclaim-3, Tecentriq, Dose Escalation, FDA Fast Track, Orphan Drug Designation